Pre-market Movers: BROS, SLS, DTST, BYND, CISO…

us pre market 053119 12may22 lt

The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).

In the Green

SELLAS Life Sciences Group, Inc. (SLS) is up over 28% at $2.75
Data Storage Corporation (DTST) is up over 27% at $2.69
Coupang, Inc. (CPNG) is up over 16% at $11.28
AppLovin Corporation (APP) is up over 15% at $31.40
Avaya Holdings Corp. (AVYA) is up over 14% at $6.70
Humanigen, Inc. (HGEN) is up over 13% at $2.04
NeuroMetrix, Inc. (NURO) is up over 12% at $3.17
Koss Corporation (KOSS) is up over 10% at $5.82
Inspirato Incorporated (ISPO) is up over 8% at $5.33

In the Red

Dutch Bros Inc. (BROS) is down over 43% at $19.27
Beyond Meat, Inc. (BYND) is down over 25% at $19.47
Cerberus Cyber Sentinel Corporation (CISO) is down over 17% at $3.67
Redbox Entertainment Inc. (RDBX) is down over 16% at $2.68
Swvl Holdings Corp. (SWVL) is down over 13% at $5.27
Silvergate Capital Corporation (SI) is down over 7% at $66.24
MicroStrategy Incorporated (MSTR) is down over 6% at $158.08
Full Truck Alliance Co. Ltd. (YMM) is down over 6% at $5.65

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT